Terapi Farmakologi Pada Wanita Hamil Yang Terinfeksi Sars-Cov-2

COVID-19 is a new disease caused by a new strain of coronavirus, SARS-CoV-2 since the end of 2019. This pandemic is still ongoing and study about new evidences on etiopathogenesis, diagnosis, and therapy are updated daily. At this time, there there isn't any yet evidence to recommend specific COVID-19 therapies for either the pregnant or non-pregnant groups of women. RCTs and large-scale clinical trials of COVID-19 drugs are still ongoing.. This literature study is a narrative review that explores nine primary research literature on available pharmacological treatment options in pregnant women infected with SARS-CoV-2 through the Pubmed and ScienceDirect databases based on established inclusion and exclusion criteria. The most common types of therapy are: Remdesivir (Antivirus), Lopinavir/ritonavir (Antivirus); Hydroxychloroquine (Antimalaria); Ceftriaxone (Antibiotic); and Dexamethasone (Corticosteroid). The maternal mortality rate is 8.8% (9 from 102 mother) and for the infant is 10.7% (11 from 103 infant). While the cure rate is 91.7% (93 from 102 participants). The highest number of pregnant women infected with SARS-CoV-2 were cesarean delivery, preterm delivery, and increased ALT and AST values. The most common neonatal outcome is the incidence of LBW